[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"erectile-dysfunction-associated-with-type-2-diabetes-mellitus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:erectile-dysfunction-associated-with-type-2-diabetes-mellitus":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100617508","phase-2-clinical-trial-investigating-the-effect-of-exosomes-as-a-complementary-treatment-in-severe-to-moderate-erectile-dysfunction-100617508",false,"NCT07319533","Clinical Trial Investigating the Effect of Exosomes as a Complementary Treatment in Severe to Moderate Erectile Dysfunction","Investigating the Effect of Exosome Derived From Human Fetal Umbilical Cord Mesanchymal Cells as Complimintary Treatment in Moderate to Severe Erectile Dysfunction","MSC","Inclusion Criteria:\n\nModerate or severe erectile dysfunction (according to IIEF-5) Non-satisfactory response to other treatments Generally Healthy males Not having severe past medical history\n\nExclusion Criteria:\n\nKnown allergy or history of hyperactivity to biological substances Peyronie's plaque Existing medical condition (severe or uncontrolled) Use of psychiatric medication Use of thyroid medication Hyopgonadism Hypergonadism Cancer History of prostatectomy Prostitis Autoimmune disease Recent trauma or surgery Ongoing systemic infection Skin lesion or infection at the site of injection","MALE","18 Years","70 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this clinical trial is to Investigate the Effect of Injection of MSC-Derived Exosome on Patients with Erectile Dysfunction in overall healthy males, aged 18-70, with-out any severe active medical condition, with moderate to severe erectile dysfunction based on IIEF-5, and non-satisfactory response to other treatments (5PDEI). The main question it aims to answer is:\n\n• Is MSC-derived exosome safe and effective in treating patients with ED by improving IIEF-5 score?\n\nIf there is a comparison group: Researchers will compare the intervention group (Exosome receiving group) with control group (placebo receiving group) to see if exosomes are safe and effective in treating male adult patients with moderate-sever ED.\n\nParticipants will receive six weekly injections of normal saline or exosome (based on group), and will undergo necessarily follow up, and examinations and observation.",[28,29,30,31,32,33],"Erectile Dysfunction","Erectile Dysfunction Associated With Type 2 Diabetes Mellitus","Erectile Dysfunction Due to Arterial Disease","Erectile Dysfunction Due to Arterial Insufficiency","Erectile Dysfunction Due to General Medical Condition","Erectile Dysfunction Due to Neuropathy",[28,35,36,15],"Exosome","Mesanchymal Stem Cell","NOT_YET_RECRUITING","2025-12-21",{"date":40,"type":41},"2026-01-06","ACTUAL",{"date":43,"type":22},"2026-01",{"date":45,"type":22},"2027-01",{"name":47,"class":48},"Labbafinejad Medical Center","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":49},"100562618","regenerative-injection-of-stem-cells-or-stem-cell-derived-exosomes-for-erectile-dysfunction-rise-100562618","NCT06605508","Regenerative Injection of Stem Cells or Stem Cell-derived Exosomes for Erectile Dysfunction (RISE)","Prospective Observational Study on Intracavernosal Injection of Autologous Adipose Tissue-Derived Stem Cells (ADSC) or Stem Cell-derived Exosomes for the Treatment of Erectile Dysfunction","RISE","Inclusion Criteria:\n\n* Age: Adult males aged 30 to 75 years.\n* Diagnosis: Confirmed diagnosis of erectile dysfunction (ED) of mild to moderate severity, as defined by an International Index of Erectile Function (IIEF) score.\n* Treatment Response: Failure or suboptimal response to conventional ED treatments, such as PDE-5 inhibitors.\n* General Health: Overall good health without contraindications to stem cell therapy.\n* Informed Consent: Ability and willingness to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Severe Cardiovascular Disease: Presence of severe cardiovascular conditions, including uncontrolled hypertension or significant heart disease.\n* Active Infections: Ongoing infections that could interfere with treatment or pose a risk to the participant.\n* Malignancies: History of or current cancer, including malignancies that could affect safety or treatment outcomes.\n* Contraindications to Stem Cell Therapy: Any medical conditions or treatments that contraindicate the use of stem cell therapy.\n* Uncontrolled Diabetes: Poorly controlled diabetes or other metabolic disorders that could impact treatment efficacy or safety.\n* Psychiatric or Cognitive Impairments: Significant psychiatric or cognitive disorders that may affect the participant\\'s ability to comply with study protocols or provide informed consent.\n* Recent Surgery or Trauma: Recent major surgeries or physical trauma that could impact the study or interfere with the intervention.\n* Participation in Other Studies: Participation in other clinical trials or studies that may affect the outcomes or safety of this study.","30 Years","75 Years",{"count":61,"type":22},30,"OBSERVATIONAL","The goal of this prospective observational study is to evaluate whether injections of stem cells derived from the patient's own fat tissue (adipose tissue) can improve erectile function in men aged 30 to 75 who have erectile dysfunction (ED) and have not responded well to standard treatments like PDE-5 inhibitors (e.g., Viagra).\n\nThe main questions the study aims to answer are:\n\nWill the stem cell injections improve erectile function, as measured by the International Index of Erectile Function (IIEF) score? Are there any changes in blood flow to the penis, which will be measured using a Doppler ultrasound?\n\nParticipants will:\n\nReceive injections of their own stem cells (obtained from a biopsy of fat) directly into the penis.\n\nUndergo assessments to check erectile function before and after treatment. Have follow-up visits at 3, 6, 9, and 12 months to monitor long-term effects. The study will also look for any possible side effects or complications and evaluate biological markers in the penis that may indicate the effectiveness of the treatment.\n\nParticipants will be recruited from clinic where they are already receiving care for ED. To take part, they must be in good overall health, with no severe heart disease, uncontrolled diabetes, cancer, or other conditions that could make stem cell therapy unsafe for them.",[28,29,65],"Erectile Dysfunction Following Radical Prostatectomy",[67,68,69,70,71],"stem cell therapy","Erectile dysfunction (ED)","Autologous adipose tissue-derived stem cells (ADSC)","Regenerative medicine for ED","Exosomes","RECRUITING","2025-08-25",{"date":75,"type":41},"2025-08-26",{"date":77,"type":41},"2025-01-10",{"date":79,"type":22},"2029-12-31",{"name":81,"class":48},"Jumeirah American Clinic",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":17,"minAge":58,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100590057","daily-tadalafil-in-diabetic-ed-patients-100590057","NCT06962462","Daily Tadalafil in Diabetic ED Patients","Effect of Daily Tadalafil Therapy on Endothelin-1 and E-Selectin in Diabetic Patients With Erectile Dysfunction","Inclusion Criteria:\n\nMale patients aged between 30 and 60 yearsز Diagnosed with diabetes mellitus Suffering from erectile dysfunction No history of hypertension or other systemic diseases\n\nExclusion Criteria:\n\nHistory of pelvic trauma or major pelvic surgery Pacientes con hipogonadismo o hiperprolactinemia Chronic liver disease or cardiovascular disorders Chronic use of central nervous system drugs, anti-androgenic drugs, or Tramadol Smokers Non-vasculogenic erectile dysfunction Known allergy to tadalafil",true,"60 Years",{"count":92,"type":22},60,[94],"NA","This study evaluates the effect of 5 mg daily tadalafil therapy on serum levels of Endothelin-1 and E-selectin in diabetic male patients with erectile dysfunction. Outcomes will be compared pre- and post-treatment versus healthy controls.",[29],[98],"Tadalafil, Endothelin-1, E-selectin, Diabetic complications, Sexual dysfunction, ELISA","2025-05-07",{"date":101,"type":41},"2025-05-08",{"date":103,"type":22},"2025-05-05",{"date":105,"type":22},"2025-08-30",{"name":107,"class":48},"South Valley University"]